Vanda Strikes Out at the Supreme Court
April 22, 2024, 3:57 PM
Two weeks ago we discussed Vanda Pharmaceuticals’ ambitious cert petition asking the Supreme Court to discontinue the “reasonable expectation of success” standard for patent obviousness that for decades has been a mainstay of patent law.
Vanda argued that the Court should instead adopt a “predictable results” standard, which would have made patents more difficult to challenge and thereby significantly impacted the pharma and biologics industries. Unsurprisingly, the Court today denied Vanda’s petition, leaving the obviousness standard unchanged.
To subscribe to our publications, click here.
Tags
News & Insights
News & Insights
American Bar Association 2025 Asia-Pacific Conference
Speaking Engagement
Antitrust
Consumer Brands CPG Legal Forum 2025
Speaking Engagement
Antitrust
Noerr Competition Day 2025
Speaking Engagement
Antitrust
NBA Commercial Law Section 38th Annual Corporate Counsel Conference
Sponsorship
Antitrust
GCR Live: Law Leaders Global 2025
Speaking Engagement
Antitrust
The 32nd Annual Marketing Partner Forum
Event
SABA North America Corporate Counsel Retreat 2025
Sponsorship
Antitrust
FTC and State AGs File “Right to Repair” Lawsuit Against Deere & Co.
Axinn Viewpoints
Antitrust
Working the Headline-Grabbing Antitrust Cases as a Junior Associate with Axinn: Google Ad Tech
Speaking Engagement
Axinn Participates in Diversity Lab’s Counsel Spotlight
Diversity, Equity & Inclusion